[Monocomponent insulins (author's transl)].
"Monocomponent" insulins (M. C. insulins) are characterized by a high degree of purity. They do not stimulate the production of antibodies at all or only very slightly, reduce insulin resistance and allergic reactions, cause lipodystrophies to disappear and lower the insulin requirement. The author was able to confirm this from his own experience. With the exception of one Australian team, other authors also judge M. C. insulins favorably. Whether these insulins can also reduce vascular complications cannot yet be finally decided.
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D003920:Diabetes Mellitus / Q000188:drug therapy / Q000235:genetics; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy; D003925:Diabetic Angiopathies / Q000517:prevention & control; D004341:Drug Evaluation; D006801:Humans; D007330:Insulin Antibodies; D007333:Insulin Resistance; D049528:Insulin, Long-Acting / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged
D007330:Insulin Antibodies; D049528:Insulin, Long-Acting
Monocomponent-Insuline.